ALGN Stock Analysis — Align Technology
Sector: Medical Devices
AI Verdict
ALGN trades at a big discount to the sector on next year's earnings for blockbuster growth, so if its digital workflow moat holds, this looks cheap for the upside.
Competitive Moat
Align Technology dominates clear dental aligners with its Invisalign brand, protected by a vast portfolio of patents and proprietary digital treatment planning software. Its end-to-end digital workflow and established relationships with orthodontists create switching costs that deter competitors.
Summary
Align's Invisalign system and digital orthodontics platform are driving a sharp earnings rebound, with forward EPS growth expected at 106.8%.
Where It Stands
ALGN has delivered a 19.63% 1-year return, trades at 14.5x next year's earnings (well below the healthcare sector median of 22x), and sits at a neutral RSI of 57.8.
Key Metrics
- RSI: 57.8 — Neutral
- Trailing P/E: 30.0x
- Forward P/E: 14.5x
- PEG Ratio: 0.28
- Earnings Growth: +1.1%
- Revenue Growth: +0.0%
- Market Cap: $12.4B
- 1-Year Return: 19.63%
- 52-Week High: $200.44
- 52-Week Low: $122.00
Analyst Consensus
17 Buy · 6 Hold · 1 Sell (24 analysts)
Bull Case
You’re paying 14.5x forward earnings for 106.8% forecasted EPS growth, which is cheap for the growth on offer if Invisalign’s digital moat holds.
Bear Case
If the forward P/E reverts to the sector median of 22x after earnings normalize, today's low multiple could disappear quickly, especially if growth stalls and the RSI drifts higher from its current 57.8.
Catalyst to Watch
Watch for quarterly EPS surprises or new patent litigation outcomes, as either could sharply alter the growth outlook.